BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1178 related articles for article (PubMed ID: 19884550)

  • 1. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
    Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
    J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B; Semiglazov V; Pawlicki M; Pienkowski T; Tjulandin S; Manikhas G; Makhson A; Roth A; Dodwell D; Baselga J; Biakhov M; Valuckas K; Voznyi E; Liu X; Vercammen E
    J Clin Oncol; 2005 Sep; 23(25):5960-72. PubMed ID: 16087945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J; Couture F; Young S; McWatters KL; Lau CY
    J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
    Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    Grote T; Yeilding AL; Castillo R; Butler D; Fishkin E; Henry DH; DeLeo M; Fink K; Sullivan DJ
    J Clin Oncol; 2005 Dec; 23(36):9377-86. PubMed ID: 16361638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
    Rades D; Tribius S; Yekebas EF; Bahrehmand R; Wildfang I; Kilic E; Muellerleile U; Gross E; Schild SE; Alberti W
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):459-65. PubMed ID: 16584851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
    Agnihotri P; Telfer M; Butt Z; Jella A; Cella D; Kozma CM; Ahuja M; Riaz S; Akamah J
    J Am Geriatr Soc; 2007 Oct; 55(10):1557-65. PubMed ID: 17697104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.
    Mystakidou K; Kalaidopoulou O; Katsouda E; Parpa E; Kouskouni E; Chondros C; Tsiatas ML; Vlahos L
    Anticancer Res; 2005; 25(5):3495-500. PubMed ID: 16101168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
    J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased hemoglobin levels and improved quality-of-life assessments during epoetin alfa treatment in anemic cancer patients: results of a prospective, multicenter German trial.
    Reinhardt U; Tulusan A; Angermund R; Lutz H;
    Oncologist; 2005 Mar; 10(3):225-37. PubMed ID: 15793226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).
    Machtay M; Pajak TF; Suntharalingam M; Shenouda G; Hershock D; Stripp DC; Cmelak AJ; Schulsinger A; Fu KK;
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1008-17. PubMed ID: 17716826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.